tolinapant

Overview

Tolinapant is an investigational inhibitor-of-apoptosis protein (IAP) inhibitor (SMAC mimetic) targeting XIAP, BIRC2 (cIAP1), and BIRC3 (cIAP2). It is evaluated in combination with radiotherapy in nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• Tolinapant IAP inhibitor (targeting XIAP and cIAP1/2) evaluated in combination with radiotherapy in NPC; XIAP and cIAP1/2 are listed as inhibitors of apoptosis targeted to overcome EBV-driven apoptosis resistance in NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.